Literature DB >> 34463913

Systematic Analysis of Cytostatic TGF-Beta Response in Mesenchymal-Like Hepatocellular Carcinoma Cell Lines.

Medine Zeynep Gungor1,2, Merve Uysal1,2, Mehmet Ozturk1,3,4, Serif Senturk5,6,7.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most challenging malignancies, with high morbidity and mortality rates. The transforming growth factor-β (TGF-β) pathway plays a dual role in HCC, acting as both tumor suppressor and promoter. A thorough understanding of the mechanisms underlying its opposing functions is important. The growth suppressive effects of TGF-β remain largely unknown for mesenchymal HCC cells. Using a systematic approach, here we assess the cytostatic TGF-β responses and intracellular transduction of the canonical TGF-β/Smad signaling cascade in mesenchymal-like HCC cell lines.
METHODS: Nine mesenchymal-like HCC cell lines, including SNU182, SNU387, SNU398, SNU423, SNU449, SNU475, Mahlavu, Focus, and Sk-Hep1, were used in this study. The cytostatic effects of TGF-β were evaluated by cell cycle analysis, BrdU labeling, and SA-β-Gal assay. RT-PCR and western blot analysis were utilized to determine the mRNA and protein expression levels of TGF-β signaling components and cytostatic genes. Immunoperoxidase staining and luciferase reporter assays were performed to comprehend the transduction of the canonical TGF-β pathway.
RESULTS: We report that mesenchymal-like HCC cell lines are resistant to TGF-β-induced growth suppression. The vast majority of cell lines have an active canonical signaling from the cell membrane to the nucleus. Three cell lines had lost the expression of cytostatic effector genes.
CONCLUSION: Our findings reveal that cytostatic TGF-β responses have been selectively lost in mesenchymal-like HCC cell lines. Notably, their lack of responsiveness was not associated with a widespread impairment of TGF-β signaling cascade. These cell lines may serve as valuable models for studying the molecular mechanisms underlying the loss of TGF-β-mediated cytostasis during hepatocarcinogenesis.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cytostatic response; HCC cell lines; Hepatocellular carcinoma; Mesenchymal; TGF-β pathway

Mesh:

Substances:

Year:  2021        PMID: 34463913     DOI: 10.1007/s12029-021-00704-z

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  23 in total

Review 1.  Smad transcription factors.

Authors:  Joan Massagué; Joan Seoane; David Wotton
Journal:  Genes Dev       Date:  2005-12-01       Impact factor: 11.361

Review 2.  TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives.

Authors:  Francesco Dituri; Serena Mancarella; Antonio Cigliano; Annarita Chieti; Gianluigi Giannelli
Journal:  Semin Liver Dis       Date:  2018-12-26       Impact factor: 6.115

3.  Production of HBs-antigen by two new human hepatoma cell lines and its enhancement by dexamethasone.

Authors:  N Huh; T Utakoji
Journal:  Gan       Date:  1981-02

4.  Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth.

Authors:  Serif Senturk; Mine Mumcuoglu; Ozge Gursoy-Yuzugullu; Burcu Cingoz; Kamil Can Akcali; Mehmet Ozturk
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 5.  Senescence and immortality in hepatocellular carcinoma.

Authors:  Mehmet Ozturk; Ayca Arslan-Ergul; Sevgi Bagislar; Serif Senturk; Haluk Yuzugullu
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

6.  Characterization of cell lines established from human hepatocellular carcinoma.

Authors:  J G Park; J H Lee; M S Kang; K J Park; Y M Jeon; H J Lee; H S Kwon; H S Park; K S Yeo; K U Lee
Journal:  Int J Cancer       Date:  1995-07-28       Impact factor: 7.396

7.  Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA.

Authors:  M Inagaki; A Moustakas; H Y Lin; H F Lodish; B I Carr
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.

Authors:  Cédric Coulouarn; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

9.  In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment.

Authors:  Hadassa Hirschfield; C Billie Bian; Takaaki Higashi; Shigeki Nakagawa; Tizita Z Zeleke; Venugopalan D Nair; Bryan C Fuchs; Yujin Hoshida
Journal:  Exp Mol Med       Date:  2018-01-05       Impact factor: 12.153

10.  COSMIC: the Catalogue Of Somatic Mutations In Cancer.

Authors:  John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  1 in total

Review 1.  The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications.

Authors:  Medine Zeynep Gungor; Merve Uysal; Serif Senturk
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.